Search clinical trials for: BIA 9-1067

Total 33948 results

Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules

Parkinson

Canada
Bial - Portela C S.A.

Completed

A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

Parkinson's Disease

France, Russian Federation
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Parkinson Disease

Canada
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

Parkinson Disease

United States
Bial - Portela C S.A.

Completed

Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa

Parkinson Disease

Canada
Bial - Portela C S.A.

Completed

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics

Parkinson Disease

France
Bial - Portela C S.A.

Completed

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

Parkinson's Disease

Portugal, Romania, Ukraine
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites

Parkinson Disease

Switzerland
Bial - Portela C S.A.

Completed

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

Parkinson's Disease

Romania, Ukraine
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

Parkinson's Disease (PD)

Netherlands
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD)

Canada
Bial - Portela C S.A.

Completed

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide

Parkinson's Disease (PD)

Canada
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD)

Canada
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers

Parkinson
Bial - Portela C S.A.

Completed

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. (BIPARKII)

Parkinson's Disease

Portugal
Rabin Medical Center

Completed

Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

Parkinson Disease

Israel
Galderma R&D

Completed

Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma

Basal Cell Carcinoma

United States
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Parkinson's Disease

Portugal
Galderma R&D

Completed

Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses (COMET2)

Actinic Keratoses

Spain, France, Germany, Netherlands, Sweden
GE Healthcare
Laboratory Corporation of America

Completed

Study to Determine Dosage of OPTISON in Pediatric Patients

Study to Determine Dosage of OPTISON in Children Between ≥9 and <18 Years of Age Weighing ≥20 kg

United States
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects

Parkinson Disease

France
Bial - Portela C S.A.

Active, not recruiting

OpicApone Sleep dISorder (OASIS)

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation

Epilepsy
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence of Opicapone

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Effect of Food on Opicapone

Parkinson Disease
Bial - Portela C S.A.

Recruiting

OpiCapone Effect on Motor Fluctuations and pAiN (OCEAN)

Parkinson Disease

United Kingdom
Hong Kong Baptist University
The Hong Kong Jockey Club Charities Trust

Completed

The Distribution of Body Constitutions Among Hong Kong Elderly Population: A Cross-sectional Study

Nine Body Constitutions

China
University of California, Los Angeles

Withdrawn

Testing a Novel Stress-induced Eating Intervention for Cancer Prevention

7-dose Control - Progressive Muscle Relaxation Only | 5-dose - Pairs Progressive Muscle Relaxation With Fruit 5 Consecutive Days | 7-dose - Pairs Progressive Muscle Relaxation With Fruit 7 Consecutive Days | 9-dose - Pairs Progressive Muscle Relaxation With Fruit 9 Consecutive Days
AtheroGenics

Unknown

ARISE - Aggressive Reduction of Inflammation Stops Events

Myocardial Infarction | Coronary Artery Disease | Atherosclerosis | Unstable Angina

Canada, United States, United Kingdom, South Africa
Bial - Portela C S.A.

Completed

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

Parkinson's Disease
Dokuz Eylul University
Ege University

Completed

The Effect of Maximal Exercise on MMP9 and TIMP1 and The Role of MMP9 -1562 C/T and TIMP1 372 T/C Polymorphisms

MMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/C

Turkey
Rennes University Hospital

Recruiting

Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies (MISTIK)

Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib

France
Ludwig-Maximilians - University of Munich
German Research Foundation; Philipps University Marburg Medical Center

Completed

Effects of Exendin(9-39) on Gastroduodenal Motility

Digestive Physiology | Gastrointestinal Motility | Gastrointestinal Hormones | Glucagon-like Peptide 1 | Exendin (9-39)

Germany
BioChain (Beijing) Science and Technology, Inc.
Beijing 302 Hospital; Chinese PLA General Hospital; 309th Hospital of Chinese... and other collaborators

Unknown

CRC Post-surgical Assessment and Recurrence Monitoring

Colorectal Cancer

China
Bial - Portela C S.A.

Active, not recruiting

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. (ADOPTION)

Parkinson Disease

Spain, Italy, Portugal, Germany, United Kingdom
9 Meters Biopharma, Inc.

Terminated

VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.

Short Bowel Syndrome

United States

Search clinical trials for: BIA 9-1067

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations